Mn Services Vermogensbeheer B.V. Trims Stake in Solventum Corporation (NYSE:SOLV)

Mn Services Vermogensbeheer B.V. lessened its stake in shares of Solventum Corporation (NYSE:SOLV - Free Report) by 9.9% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 49,032 shares of the company's stock after selling 5,400 shares during the period. Mn Services Vermogensbeheer B.V.'s holdings in Solventum were worth $3,728,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of SOLV. Clarity Asset Management Inc. bought a new stake in Solventum in the fourth quarter valued at $25,000. Raiffeisen Bank International AG bought a new stake in shares of Solventum during the fourth quarter worth about $29,000. Colonial Trust Co SC increased its position in shares of Solventum by 240.7% during the fourth quarter. Colonial Trust Co SC now owns 511 shares of the company's stock worth $34,000 after acquiring an additional 361 shares in the last quarter. Banque Transatlantique SA bought a new stake in shares of Solventum during the fourth quarter worth about $42,000. Finally, EverSource Wealth Advisors LLC grew its position in Solventum by 48.1% in the 4th quarter. EverSource Wealth Advisors LLC now owns 687 shares of the company's stock worth $45,000 after purchasing an additional 223 shares in the last quarter.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Piper Sandler upgraded shares of Solventum from a "neutral" rating to an "overweight" rating and boosted their target price for the company from $78.00 to $87.00 in a research note on Monday, May 19th. Mizuho boosted their target price on shares of Solventum from $70.00 to $82.00 and gave the company a "neutral" rating in a research note on Monday, March 3rd. The Goldman Sachs Group boosted their target price on shares of Solventum from $63.00 to $71.00 and gave the company a "sell" rating in a research note on Monday, March 3rd. Morgan Stanley upped their price target on shares of Solventum from $73.00 to $80.00 and gave the company an "equal weight" rating in a research note on Wednesday, March 5th. Finally, KeyCorp started coverage on shares of Solventum in a report on Friday, June 6th. They set a "sector weight" rating on the stock. One analyst has rated the stock with a sell rating, eight have given a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $80.29.

Solventum Stock Up 1.2%

Shares of SOLV stock traded up $0.87 during midday trading on Friday, reaching $73.50. 1,157,440 shares of the stock were exchanged, compared to its average volume of 1,160,932. Solventum Corporation has a 1 year low of $47.16 and a 1 year high of $85.92. The company's 50 day moving average is $70.66 and its two-hundred day moving average is $71.71. The company has a current ratio of 1.19, a quick ratio of 0.85 and a debt-to-equity ratio of 2.40. The firm has a market cap of $12.72 billion, a PE ratio of 34.03, a price-to-earnings-growth ratio of 1.88 and a beta of 0.54.

Solventum (NYSE:SOLV - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $1.34 EPS for the quarter, topping analysts' consensus estimates of $1.19 by $0.15. Solventum had a return on equity of 31.01% and a net margin of 4.55%. The firm had revenue of $2.07 billion for the quarter, compared to analysts' expectations of $2.02 billion. During the same period in the previous year, the firm posted $2.08 EPS. The business's revenue for the quarter was up 2.7% compared to the same quarter last year. On average, equities research analysts predict that Solventum Corporation will post 6.58 EPS for the current year.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.